Spyre Therapeutics Files 8-K with Key Corporate Updates
Ticker: SYRE · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $1,480, $180.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-governance
TL;DR
Spyre Therapeutics filed an 8-K on 3/18/24 covering material agreements, equity sales, and charter amendments.
AI Summary
On March 18, 2024, Spyre Therapeutics, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, unregistered sales of equity securities, amendments to its articles of incorporation, and Regulation FD disclosures. The company, formerly known as Aeglea BioTherapeutics, Inc., is based in Waltham, MA.
Why It Matters
This 8-K filing signals significant corporate actions and potential changes for Spyre Therapeutics, including financial transactions and governance updates that could impact investors.
Risk Assessment
Risk Level: medium — The filing indicates unregistered sales of equity securities and amendments to corporate documents, which can introduce complexities and potential risks for investors.
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Registrant
- Aeglea BioTherapeutics, Inc. (company) — Former company name
- March 18, 2024 (date) — Date of earliest event reported
- Waltham, MA (location) — Company business address
FAQ
What is the nature of the material definitive agreement entered into by Spyre Therapeutics?
The filing indicates the entry into a material definitive agreement but does not provide specific details about its nature in the provided text.
What were the details of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities as an item of disclosure but does not provide specific details on the number of shares, price, or purchasers in the provided text.
What specific amendments were made to Spyre Therapeutics' articles of incorporation or bylaws?
The filing lists amendments to articles of incorporation or bylaws as an item, but the specific changes are not detailed in the provided text.
What is the significance of the Regulation FD Disclosure?
The Regulation FD Disclosure item indicates that the company is providing information to the public in accordance with fair disclosure rules, often related to material non-public information.
When did Aeglea BioTherapeutics, Inc. change its name to Spyre Therapeutics, Inc.?
The date of the name change from Aeglea BioTherapeutics, Inc. to Spyre Therapeutics, Inc. was March 11, 2015.
Filing Stats: 1,904 words · 8 min read · ~6 pages · Grade level 12.7 · Accepted 2024-03-18 08:31:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share SYRE The Nasdaq
- $1,480 — erred Stock "), at a price per share of $1,480.00, for an aggregate purchase price of
- $180.0 million — gregate purchase price of approximately $180.0 million. Each Preferred Share is convertible in
Filing Documents
- d784263d8k.htm (8-K) — 41KB
- d784263dex32.htm (EX-3.2) — 6KB
- d784263dex101.htm (EX-10.1) — 317KB
- d784263dex102.htm (EX-10.2) — 89KB
- d784263dex991.htm (EX-99.1) — 12KB
- g784263g0317122432784.jpg (GRAPHIC) — 4KB
- 0001193125-24-069693.txt ( ) — 702KB
- syre-20240318.xsd (EX-101.SCH) — 2KB
- syre-20240318_lab.xml (EX-101.LAB) — 19KB
- syre-20240318_pre.xml (EX-101.PRE) — 12KB
- d784263d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 18, 2024 SPYRE THERAPEUTICS, INC. By: /s/ Cameron Turtle Cameron Turtle Chief Executive Officer